| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 07/06/2000 | WO2000039128A1 5ht1 antagonists for antidepressant therapy |
| 07/06/2000 | WO2000039126A1 Method for preparing (r)- (+) -3 {1- [2-( 4-benzoyl- 2-(3,4- difluorophenyl)morpholin- 2-yl)ethyl]- 4-phenylpiperidin -4-yl}-1,1- dimethylurea, its salts solvates and/or hydrates |
| 07/06/2000 | WO2000039125A1 Piperidines as ccr5 modulators |
| 07/06/2000 | WO2000039124A1 Thrombin inhibitors |
| 07/06/2000 | WO2000039123A1 Process for the preparation of an acetate salt of paroxetine or paroxetine analogues |
| 07/06/2000 | WO2000039122A1 Process for the preparation of an acetate salt of paroxetine or paroxetine analogues |
| 07/06/2000 | WO2000039121A1 Process for the preparation of an acetate salt of paroxetine or paroxetine analogues |
| 07/06/2000 | WO2000039120A2 Compounds and methods for modulation of estrogen receptors |
| 07/06/2000 | WO2000039119A1 Novel inhibitors of farnesyl-protein transferase |
| 07/06/2000 | WO2000039118A1 Aromatic amides |
| 07/06/2000 | WO2000039117A1 HETEROROAROMATIC AMIDES AS INHIBITOR OF FACTOR Xa |
| 07/06/2000 | WO2000039115A1 Protease inhibitors |
| 07/06/2000 | WO2000039114A2 Substituted oximes and hydrazones as neurokinin antagonists |
| 07/06/2000 | WO2000039113A1 Benzopyrans and benzoxepines, pharmaceutical compositions comprising them and preparation process |
| 07/06/2000 | WO2000039111A1 Antithrombotic amides |
| 07/06/2000 | WO2000039110A1 Homopiperazine derivatives as selective emopamil inhibitors |
| 07/06/2000 | WO2000039108A1 Thrombin or factor xa inhibitors |
| 07/06/2000 | WO2000039105A1 1,4-diazacycloheptane derivatives useful in the treatment of neurological disorders |
| 07/06/2000 | WO2000039102A1 THROMBIN OR FACTOR Xa INHIBITORS |
| 07/06/2000 | WO2000039101A1 Pyrimidine compounds |
| 07/06/2000 | WO2000039097A1 Imidazole compounds and medicinal use thereof |
| 07/06/2000 | WO2000039096A1 2-methylimidazoline compounds |
| 07/06/2000 | WO2000039095A2 Phenethyl-5-bromopyridylthiourea (pbt) and dihydroalkoxybenzyloxopyrimidine (dabo) derivatives exhibiting spermicidal activity |
| 07/06/2000 | WO2000039092A1 HETEROCYCLIC AMIDES AS INHIBITORS OF FACTOR Xa |
| 07/06/2000 | WO2000039091A1 3,3-biarylpiperidine and 2,2-biarylmorpholine derivatives |
| 07/06/2000 | WO2000039090A1 Process for the preparation of paroxetine acetate and analogues thereof |
| 07/06/2000 | WO2000039089A1 3-azabicyclo[3.1.0.] hexane derivatives as opiate receptors ligands |
| 07/06/2000 | WO2000039088A1 Glucagon antagonists/inverse agonists |
| 07/06/2000 | WO2000039087A2 Substituted (aminoiminomethyl or aminomethyl)benzoheteroaryl compounds as factor xa inhibitors |
| 07/06/2000 | WO2000039086A1 Aromatic heterocycle compounds having hiv integrase inhibiting activities |
| 07/06/2000 | WO2000039083A2 Pyrazole compounds and uses thereof |
| 07/06/2000 | WO2000039082A2 1,2-annelated quinoline derivatives |
| 07/06/2000 | WO2000039081A2 Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds |
| 07/06/2000 | WO2000039077A2 Thyroid receptor ligands |
| 07/06/2000 | WO2000039070A1 Ortho-diphenol compounds, methods and pharmaceutical compositions for inhibiting parp |
| 07/06/2000 | WO2000038811A1 Apparatus and process for preparing crystalline particles |
| 07/06/2000 | WO2000038786A2 Use of cyclooxygenase 2 inhibitor and an integrin antagonist as a combination therapy in the treatment of neoplasia |
| 07/06/2000 | WO2000038785A2 Methods for treating certain diseases using naaladase inhibitors |
| 07/06/2000 | WO2000038747A2 Absorbent article composition and method of use for sequestering skin irritants |
| 07/06/2000 | WO2000038738A1 Blood pool agents for nuclear magnetic resonance diagnostics |
| 07/06/2000 | WO2000038734A1 Anthraquinone anticancer drugs |
| 07/06/2000 | WO2000038732A1 Hyaluronate lyase used for promoting penetration in topical agents |
| 07/06/2000 | WO2000038730A2 Use of a cyclooxygenase-2 inhibitor and one or more antineoplastic agents for combination therapy in neoplasia |
| 07/06/2000 | WO2000038729A1 Combinations of ileal bile acid transport inhibitors and nicotinic acid derivatives for cardiovascular indications |
| 07/06/2000 | WO2000038728A1 Combinations of ileal bile acid transport inhibitors and bile acid sequestring agents for cardiovascular indications |
| 07/06/2000 | WO2000038727A1 Combinations of ileal bile acid transport inhibitors and fibric acid derivatives for cardiovascular indications |
| 07/06/2000 | WO2000038726A1 Combinations of ileal bile acid transport inhibitors and cholesteryl ester transfer protein inhibitors for cardiovascular indications |
| 07/06/2000 | WO2000038725A1 Combinations for cardiovascular indications |
| 07/06/2000 | WO2000038724A1 Combinations of cholesteryl ester transfer protein inhibitors and fibric acid derivatives for cardiovascular indications |
| 07/06/2000 | WO2000038723A1 Combinations of cholesteryl ester transfer protein inhibitors and bile acid sequestering agents for cardiovascular indications |
| 07/06/2000 | WO2000038722A1 COMBINATIONS OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS AND HMG CoA REDUCTASE INHIBITORS FOR CARDIOVASCULAR INDICATIONS |
| 07/06/2000 | WO2000038721A1 Combinations of cholesteryl ester transfer protein inhibitors and nicotinic acid derivatives for cardiovascular indications |
| 07/06/2000 | WO2000038720A1 Remedies for pain |
| 07/06/2000 | WO2000038719A1 Use of a matrix metalloproteinase inhibitor and an integrin antagonist in the treatment of neoplasia |
| 07/06/2000 | WO2000038718A2 Use of matrix metalloproteinase inhibitor together with an antineoplastic agents, optionally also together with radiation, in the treatment of neoplasia |
| 07/06/2000 | WO2000038717A2 Use of a matrix metalloproteinase inhibitor and radiation as a combined treatment of neoplasia |
| 07/06/2000 | WO2000038716A1 Combination therapy of radiation and a cox-2 inhibitor for the treatment of neoplasia |
| 07/06/2000 | WO2000038715A2 Use of an integrin antagonist and radiation in the treatment of neoplasia |
| 07/06/2000 | WO2000038709A1 Treatment of hyperproliferative disorders using casein kinase i |
| 07/06/2000 | WO2000038707A1 Method for the treatment of bone loss |
| 07/06/2000 | WO2000038706A2 Methods for treating cancer and for mediating chemotaxis of dendritic cells |
| 07/06/2000 | WO2000038704A1 Use of peptide |
| 07/06/2000 | WO2000038703A1 Agent for treating visual cell function disorder |
| 07/06/2000 | WO2000038700A1 Antiprotozoal saponins |
| 07/06/2000 | WO2000038697A1 Treatment and prevention of hiv and other viral infections |
| 07/06/2000 | WO2000038696A1 Cyanocobalamin (vitamin b12) treatment in allergic disease |
| 07/06/2000 | WO2000038695A2 Aciclovir compositions containing dimethicone |
| 07/06/2000 | WO2000038694A1 Medicinal compositions for treating osseous lesion in multiple myeloma |
| 07/06/2000 | WO2000038693A1 Interleukin-6 production inhibitors |
| 07/06/2000 | WO2000038692A1 Cystic fibrosis remedies containing vitamin d3 derivatives |
| 07/06/2000 | WO2000038691A1 Triphasic oral contraceptive |
| 07/06/2000 | WO2000038690A2 Prostaglandin e agonists for treatment of dry eye |
| 07/06/2000 | WO2000038689A1 Drug compositions for the treatment of ocular hypertension or glaucoma |
| 07/06/2000 | WO2000038687A1 Protease inhibitors |
| 07/06/2000 | WO2000038686A1 Controlled release galantamine composition |
| 07/06/2000 | WO2000038684A1 (2-imidazolin-2-ylamino) quinoxaline derivatives for the treatment of pain |
| 07/06/2000 | WO2000038683A1 THROMBIN OR FACTOR Xa INHIBITORS |
| 07/06/2000 | WO2000038682A1 Anti-hiv infection agents and method for treating hiv infection |
| 07/06/2000 | WO2000038681A1 Liposomic niflumic acid - new transdermal anti-inflammatory medicine |
| 07/06/2000 | WO2000038680A1 Azabicycloalkanes as ccr5 modulators |
| 07/06/2000 | WO2000038679A1 Treatment of retroviral infections with oxyphenbutazone |
| 07/06/2000 | WO2000038678A1 Composition used as medicine and use of same for obtaining a medicine for anaesthesia, in particular analgesic medicine |
| 07/06/2000 | WO2000038677A1 Indole and indolizidine derivatives for the treatment of migraine |
| 07/06/2000 | WO2000038676A1 Use of at-1 receptor antagonist or at-2 receptor modulator for treating diseases associated with an increase of at-1 or at-2 receptors |
| 07/06/2000 | WO2000038675A1 Treatment of conditions with a need for the inhibition of gsk-3 |
| 07/06/2000 | WO2000038674A1 COMPOUNDS WHICH AFFECT mRNA STABILITY AND USES THEREFOR |
| 07/06/2000 | WO2000038672A2 Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy |
| 07/06/2000 | WO2000038671A1 Method for the preparation of a pharmaceutical composition |
| 07/06/2000 | WO2000038670A1 Propanolol metabolites useful for antioxidant activities |
| 07/06/2000 | WO2000038669A2 Use of naloxone for preventing and treating the degeneration of neurons |
| 07/06/2000 | WO2000038668A2 Use of a nitrosourea derivative for prevention or treatment of acute allograft rejection |
| 07/06/2000 | WO2000038667A2 Prostaglandin e agonists for treatment of glaucoma |
| 07/06/2000 | WO2000038666A2 A COMBINATION OF FBPase INHIBITORS AND INSULIN SENSITIZERS FOR THE TREATMENT OF DIABETES |
| 07/06/2000 | WO2000038665A2 Use of an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia |
| 07/06/2000 | WO2000038664A2 Amine condensation polymer bile acid sequestrants |
| 07/06/2000 | WO2000038663A2 Ep4 receptor agonists for treatment of dry eye |
| 07/06/2000 | WO2000038662A2 The manipulation of the activity of a nitric oxide radical production pathway for the treatment of diseases associated with the presence of oxygen free radicals |
| 07/06/2000 | WO2000038661A2 The utilisation of inhibitors of the sodium hydrogen exchanger for producing a medicament for preventing organ dysfunctions and diseases related to a particular age and for prolonging life |
| 07/06/2000 | WO2000038660A2 Use of bisphosphonates for the prevention and treatment of infectious processes |
| 07/06/2000 | WO2000038659A1 Transdermal drug delivery system |